November 3, 2021 -- Data from ImmunoGenesis will be presented at the Society for Immunotherapy of Cancer (SITC) annual meeting scheduled for November 10-14 in Washington, DC.
The following research titles will be presented:
- "Human PD-L2 Triggers a Unique T Cell Inhibitory Program Through PD-1 Engagement Distinct Dual-Specific Antibodies Blocking Both PD-L1 and PD-L2 Engagement of PD-1 Restore Anti-Tumor Immunity"
- "High-Potency Synthetic STING Agonists Rewire the Myeloid Stroma in the Tumor Microenvironment to Amplify Immune Checkpoint Blockade Efficacy in Refractory Pancreatic Ductal Adenocarcinoma"
- "Intratumoral Delivery of High Potency STING Agonists Modulates the Immunosuppressive Myeloid Compartment and Induces Curative Responses in Checkpoint-Refractory Glioblastoma Models"
- "Disrupted Oxygen Supply and Tumor Hyper-Oxygen Consumption Contribute Independently to Prostate Cancer Immune Privilege"
- "Hypoxia Reduction in Tandem With Anti-Angiogenic Therapy Remodels the PDAC Microenvironment and Potentiates CD40 Agonist Therapy"
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
